(Q44641540)

English

Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and β-lactams tested against gram-negative bacilli

scientific article published on November 1, 2003

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against gram-negative bacilli (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and β-lactams tested against gram-negative bacilli (English)

1 reference

10.1016/S0732-8893(03)00158-5

https://api.crossref.org/works/10.1016/S0732-8893(03)00158-5

28 March 2024

Gram-negative bacteria

0 references

1 reference

based on heuristic

inferred from title

1

object named as

Helio S Sader

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

3

object named as

Ronald N Jones

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

author name string

Holly K. Huynh

2

0000-0002-1189-1895

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14596974

28 March 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14596974

28 March 2024

publication date

1 November 2003

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0732889303001585?httpAccept=text/xml

1 reference

10.1016/S0732-8893(03)00158-5

https://api.crossref.org/works/10.1016/S0732-8893(03)00158-5

28 March 2024

https://api.elsevier.com/content/article/PII:S0732889303001585?httpAccept=text/plain

1 reference

10.1016/S0732-8893(03)00158-5

https://api.crossref.org/works/10.1016/S0732-8893(03)00158-5

28 March 2024

Diagnostic Microbiology and Infectious Disease

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

47

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

547-550

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

In vitro activity of aztreonam combined with tobramycin and gentamicin against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2803%2900158-5

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2803%2900158-5

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of aztreonam in combination with newer beta-lactams and amikacin against multiply resistant gram-negative bacilli

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2803%2900158-5

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of ciprofloxacin in combination with ceftazidime, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2803%2900158-5

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2803%2900158-5

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2803%2900158-5

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2803%2900158-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Aztreonam therapy in neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2803%2900158-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Antimicrobial activity of isepamicin (SCH21420, 1-N-HAPA gentamicin B) combinations with cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem, mezlocillin and piperacillin tested against gentamicin-resistant and susceptible gram-negative ba

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2803%2900158-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Antimicrobial activity of amikacin combinations against Enterobacteriaceae moderately susceptible to third-generation cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2803%2900158-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Synergy with aztreonam and arbekacin or tobramycin against Pseudomonas aeruginosa from blood

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2803%2900158-5

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2803%2900158-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against gram-negative bacilli

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2803%2900158-5

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2803%2900158-5

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of beta-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2803%2900158-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2803%2900158-5

7 January 2021

based on heuristic

inferred from DOI database lookup

An approach for the evaluation of synergy between antimicrobials

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2803%2900158-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0732-8893(03)00158-5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44641540&oldid=2113007332"